TY PHAR.(SZ:002728) Zheng Quan Zhi Xing·2025-08-15 16:24Core Viewpoint - Dongguan Securities has issued a verification opinion regarding Te Yi Pharmaceutical Group's plan to manage idle funds raised from a specific stock issuance in 2023, emphasizing the importance of efficient fund utilization while ensuring that the investment projects proceed normally [1][5]. Fundraising Overview - Te Yi Pharmaceutical raised a total of RMB 268,891,257.70 from issuing 20,146,514 shares at RMB 13.65 per share, after deducting issuance costs of RMB 874,949.91 [1][2]. - As of June 30, 2025, the company has utilized RMB 60 million of the raised funds, leaving a balance of RMB 210.48 million, which includes net interest income of RMB 1.6378 million [2]. Fund Usage and Idle Reasons - The company has temporarily supplemented working capital with RMB 200 million, which has been fully returned to the special account for raised funds [2]. - The idle funds are primarily due to the construction cycle of the modern Chinese medicine product line expansion and technology upgrade project, which has resulted in a temporary surplus of funds [2]. Cash Management Plan - The company plans to use up to RMB 90 million of the idle funds for cash management, focusing on high liquidity and safety investment products such as structured deposits and time deposits, with a maximum investment period of 12 months [3][4]. - The management will ensure that cash management does not affect the normal progress of investment projects [3]. Decision-Making Process - The board of directors has approved the cash management plan, ensuring compliance with relevant laws and regulations, and allowing for the rolling use of funds within the specified limits [4][5]. Verification Opinion - Dongguan Securities has confirmed that the cash management plan aligns with legal requirements and will not impact the company's main business operations, thereby enhancing the efficiency of idle fund utilization and potentially increasing company returns [5].